Markets:

Overview

News

Currencies

International

Treasuries

Organon & Co. Common Stock (NY:OGN)

13.55 +0.00 (+0.04%)

Streaming Delayed Price Updated: 11:56 AM EDT, Jul 31, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Organon & Co. Common Stock

< Previous 1 2

...

7 8 9 10 11 12 13 14 15

...

20 21 Next >

Here are the top movers in Thursday's session. ↗

May 01, 2025

Here are the top movers in Thursday's session, showcasing the stocks with significant price changes.

Via Chartmill

Organon & Co. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights - OGN

May 01, 2025

From DJS Law Group

Via Business Wire

OGN Investors Have Opportunity to Join Organon & Co. Fraud Investigation with the Schall Law Firm

May 01, 2025

From The Schall Law Firm

Via Business Wire

Earnings Scheduled For May 1, 2025 ↗

May 01, 2025

Via Benzinga

Top stock movements in today's session. ↗

May 01, 2025

Curious to know what's happening on the US markets in the middle of the day on Thursday? Join us as we explore the top gainers and losers in today's session.

Via Chartmill

Dow Surges Over 300 Points; McDonald's Posts Weak Revenue ↗

May 01, 2025

Via Benzinga

Topics Stocks

12 Health Care Stocks Moving In Thursday's Intraday Session ↗

May 01, 2025

Via Benzinga

The market is filled with gapping stocks in Thursday's session. ↗

May 01, 2025

There are notable gap-ups and gap-downs in today's session. Let's take a look at which stocks are gapping on Thursday.

Via Chartmill

These stocks are moving in today's pre-market session ↗

May 01, 2025

The US market is yet to commence its session on Thursday, but let's get a preview of the pre-market session and explore the top gainers and losers driving the early market movements.

Via Chartmill

Organon (NYSE:OGN) Posts Better-Than-Expected Sales In Q1 But Stock Drops 23.5%

May 01, 2025

Pharmaceutical company Organon (NYSE:OGN) reported revenue ahead of Wall Street’s expectations in Q1 CY2025, but sales fell by 6.7% year on year to $1.51 billion. Its non-GAAP profit of $1.02 per share...

Via StockStory

12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗

May 01, 2025

Via Benzinga

Organon Reports Results for the First Quarter Ended March 31, 2025

May 01, 2025

From Organon & Co.

Via Business Wire

Organon (OGN) Q1 Earnings: What To Expect

April 30, 2025

Pharmaceutical company Organon (NYSE:OGN) will be reporting earnings tomorrow before market open. Here’s what investors should know.

Via StockStory

Topics Artificial Intelligence Economy World Trade

3 Cash-Producing Stocks with Questionable Fundamentals

April 27, 2025

While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns. Some cash-heavy businesses struggle with inefficient spending, slowing demand, or weak...

Via StockStory

LGI Homes, Super Micro, Organon, Ibotta, and ManpowerGroup Stocks Trade Up, What You Need To Know

April 22, 2025

A number of stocks jumped in the afternoon session after investor sentiment improved on renewed optimism that the US-China trade conflict might be nearing a resolution. According to reports, Treasury...

Via StockStory

Topics World Trade

Organon Appoints Ramona A. Sequeira to the Company’s Board of Directors

April 15, 2025

From Organon & Co.

Via Business Wire

Organon To Report First Quarter 2025 Results and Host Conference Call on May 1, 2025

April 15, 2025

From Organon & Co.

Via Business Wire

Q4 Earnings Roundup: Organon (NYSE:OGN) And The Rest Of The Branded Pharmaceuticals Segment

April 08, 2025

Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Organon (NYSE:OGN) and the best and worst...

Via StockStory

Topics Artificial Intelligence Intellectual Property

Organon (OGN): Buy, Sell, or Hold Post Q4 Earnings?

April 07, 2025

Organon has gotten torched over the last six months - since October 2024, its stock price has dropped 29.4% to a new 52-week low of $12.79 per share. This was partly driven by its softer quarterly...

Via StockStory

A Look Back at Branded Pharmaceuticals Stocks’ Q4 Earnings: Collegium Pharmaceutical (NASDAQ:COLL) Vs The Rest Of The Pack

April 02, 2025

The end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current business environment. Let’s take a look at how Collegium Pharmaceutical...

Via StockStory

Topics Artificial Intelligence Intellectual Property

Organon Acquires TOFIDENCE™ (tocilizumab-bavi), a Commercialized Biosimilar to ACTEMRA® (tocilizumab) Injection, for Intravenous Infusion in the U.S.

April 01, 2025

From Organon & Co.

Via Business Wire

European Medicines Agency (EMA) Validates Henlius and Organon Filing for Perjeta® (pertuzumab) Biosimilar Candidate HLX11

March 28, 2025

From Organon & Co.

Via Business Wire

Unpacking Q4 Earnings: Pfizer (NYSE:PFE) In The Context Of Other Branded Pharmaceuticals Stocks

March 27, 2025

As the Q4 earnings season wraps, let’s dig into this quarter’s best and worst performers in the branded pharmaceuticals industry, including Pfizer (NYSE:PFE) and its peers.

Via StockStory

Topics Artificial Intelligence Intellectual Property

3 Small-Cap Stocks Skating on Thin Ice

March 26, 2025

Investors looking for hidden gems should keep an eye on small-cap stocks because they’re frequently overlooked by Wall Street. Many opportunities exist in this part of the market, but it is also a...

Via StockStory

1 Healthcare Stock with Solid Fundamentals and 2 to Turn Down

March 21, 2025

From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. But financial performance has lagged recently as players offloaded surplus COVID...

Via StockStory

Topics Stocks

Q4 Earnings Highs And Lows: Royalty Pharma (NASDAQ:RPRX) Vs The Rest Of The Branded Pharmaceuticals Stocks

March 21, 2025

The end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current business environment. Let’s take a look at how Royalty Pharma (NASDAQ:RPRX)...

Via StockStory

Topics Artificial Intelligence Intellectual Property

New Analysis of Organon’s VTAMA® (tapinarof) cream, 1% Phase 3 Data Shows Atopic Dermatitis Disease Activity Remained Low After Treatment-Free Interval in Adults and Children 2 Years of Age and Older

March 08, 2025

From Organon & Co.

Via Business Wire

Q4 Earnings Outperformers: Corcept (NASDAQ:CORT) And The Rest Of The Branded Pharmaceuticals Stocks

March 04, 2025

As the Q4 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the branded pharmaceuticals industry, including Corcept (NASDAQ:CORT) and its peers.

Via StockStory

Topics Artificial Intelligence Intellectual Property

Wall Street's Most Accurate Analysts Weigh In On 3 Health Care Stocks With Over 4% Dividend Yields ↗

February 19, 2025

Via Benzinga

High-Yield Healthcare: 3 Stocks With Strong Dividends

February 16, 2025

This article covers three healthcare stocks that offer dividend yields of at least 7% and dives deeper into the fundamentals to determine if they're good buys.

Via MarketBeat

< Previous 1 2

...

7 8 9 10 11 12 13 14 15

...

20 21 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.